Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis
Sponsor: MoonLake Immunotherapeutics AG
Listed as NCT05640245, this PHASE2 trial focuses on Arthritis, Psoriatic and remains completed. Sponsored by MoonLake Immunotherapeutics AG, it has been updated 14 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Dec 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MoonLake Immunotherapeutics AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Budapest, Hungary , Bydgoszcz, Poland , Duncansville, United States , Elblag, Poland , Gdynia, Poland , Hamburg, Germany , Herne, Germany , Krakow, Poland , Lodz, Poland and 25 more locations